Evaluating camrelizumab and apatinib for advanced gastric cancer
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
This study is testing how safe and effective the combination of camrelizumab and apatinib is for people with advanced gastric cancer, compared to using them alone or with chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 504 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Changzhi People's Hospital Affiliated to Changzhi Medical College Academic / other |
| Drugs / interventions | karelizumab, apatinib, immunotherapy, camrelizumab |
| Locations | 1 site (Changzhi, Shanxi) |
| Trial ID | NCT06485271 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the safety and efficacy of camrelizumab alone or in combination with apatinib and chemotherapy in patients with advanced gastric cancer. It focuses on real-world conditions and various subgroups of gastric cancer patients to gather information on treatment modalities and efficacy. Patients are enrolled based on their disease stage and prior treatment history, with the goal of exploring potential predictive biomarkers for prognosis.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with advanced gastric cancer who have measurable lesions and are amenable to treatment with camrelizumab or apatinib.
Not a fit: Patients who are pregnant, lactating, or have previously used certain immunotherapy or anti-angiogenic agents may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into effective treatment options for advanced gastric cancer patients.
How similar studies have performed: While this study explores a combination of therapies, similar approaches in other studies have shown promise in treating advanced gastric cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years old, both male and female; 2. patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment; 3. Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm; 4. The investigator determines that the patient is amenable to treatment with karelizumab or apatinib; 5. Voluntary enrollment; good compliance and willingness to cooperate with follow-up. Exclusion Criteria: 1. Pregnant or lactating women; 2. Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.); 3. Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.); 4. Patients who, in the judgment of the investigator, are not suitable for inclusion.
Where this trial is running
Changzhi, Shanxi
- Changzhi People's Hospital Affiliated to Changzhi Medical College — Changzhi, Shanxi, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.